- Home
- SPRY vs BCSF Comparison
SPRY vs BCSF Comparison
Compare SPRY & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPRY | BCSF |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 761.6M | 799.8M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPRY | BCSF |
|---|---|---|
| Price | $8.25 | $12.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $40.00 | $14.00 |
| AVG Volume (30 Days) | ★ 1.5M | 504.9K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 15.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.53 |
| Revenue | ★ $84,278,000.00 | N/A |
| Revenue This Year | $90.76 | N/A |
| Revenue Next Year | $81.70 | N/A |
| P/E Ratio | ★ N/A | $8.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.66 | $11.82 |
| 52 Week High | $18.63 | $16.00 |
Technical Indicators
Market Signals| Indicator | SPRY | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 51.06 |
| Support Level | $6.93 | $12.49 |
| Resistance Level | $8.70 | $14.53 |
| Average True Range (ATR) | 0.58 | 0.33 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 57.71 | 95.01 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.